Exactech (EXAC) Earning Somewhat Favorable News Coverage, Report Finds

Media coverage about Exactech (NASDAQ:EXAC) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Exactech earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.2780898001385 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Exactech (NASDAQ EXAC) opened at $50.45 on Friday. Exactech has a 1 year low of $23.30 and a 1 year high of $50.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.08 and a quick ratio of 2.09. The firm has a market cap of $724.77, a price-to-earnings ratio of 5,045.00, a P/E/G ratio of 3.65 and a beta of 1.02.

Exactech (NASDAQ:EXAC) last posted its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.03). Exactech had a net margin of 0.18% and a return on equity of 7.22%. The firm had revenue of $61.40 million during the quarter, compared to analysts’ expectations of $61.78 million. equities analysts anticipate that Exactech will post 1.29 earnings per share for the current year.

EXAC has been the topic of a number of analyst reports. Robert W. Baird set a $34.00 price objective on shares of Exactech and gave the company a “buy” rating in a research report on Sunday, October 15th. Sidoti lowered shares of Exactech from a “buy” rating to a “neutral” rating in a research report on Monday, October 23rd. Gabelli lowered shares of Exactech from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Zacks Investment Research lowered shares of Exactech from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. Finally, ValuEngine lowered shares of Exactech from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Six investment analysts have rated the stock with a hold rating, The company currently has a consensus rating of “Hold” and an average price target of $49.00.

COPYRIGHT VIOLATION WARNING: “Exactech (EXAC) Earning Somewhat Favorable News Coverage, Report Finds” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.com-unik.info/2018/01/12/exactech-exac-earning-somewhat-favorable-news-coverage-report-finds.html.

Exactech Company Profile

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Insider Buying and Selling by Quarter for Exactech (NASDAQ:EXAC)

What are top analysts saying about Exactech? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Exactech and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit